How it works

LIAISON XS, the new platform targeting small size laboratories launched in Europe in 2019, currently also available in the U.S. market.

Category
new platforms development
Technology
Immunodiagnostics
Rationale
Penetrate a new market segment all over the world: Physician Office Labs in the U.S., Class I and II Hospitals in China and medium size hospitals in Europe to replace the older LIAISON platforms and to drive the conversion of clients using ELISA technology (e.g. Siemens, Qiagen) to CLIA.
How it connects with the strategy
Increase penetration in small size labs.

LIAISON XS new platform